Ocular Therapeutix (NASDAQ:OCUL) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.

Several other equities analysts have also recently weighed in on OCUL. HC Wainwright set a $10.00 price target on Ocular Therapeutix and gave the company a “buy” rating in a research report on Friday, July 20th. Zacks Investment Research upgraded Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Tuesday, August 14th. Cantor Fitzgerald set a $22.00 price target on Ocular Therapeutix and gave the company a “buy” rating in a research report on Thursday, July 19th. BidaskClub cut Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Wednesday, July 4th. Finally, Piper Jaffray Companies started coverage on Ocular Therapeutix in a research report on Thursday, September 6th. They issued an “overweight” rating for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $12.00.

NASDAQ:OCUL opened at $6.20 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 4.92 and a quick ratio of 4.91. Ocular Therapeutix has a 1 year low of $3.30 and a 1 year high of $8.28. The firm has a market capitalization of $254.71 million, a price-to-earnings ratio of -2.82 and a beta of 1.21.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.37). Ocular Therapeutix had a negative return on equity of 143.32% and a negative net margin of 2,814.72%. The business had revenue of $0.65 million during the quarter, compared to the consensus estimate of $0.35 million. equities research analysts predict that Ocular Therapeutix will post -1.53 EPS for the current fiscal year.

In other Ocular Therapeutix news, CFO Donald Notman bought 12,500 shares of Ocular Therapeutix stock in a transaction that occurred on Tuesday, August 14th. The stock was acquired at an average cost of $6.29 per share, for a total transaction of $78,625.00. Following the completion of the transaction, the chief financial officer now directly owns 17,300 shares in the company, valued at $108,817. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Antony C. Mattessich bought 16,900 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, August 10th. The shares were acquired at an average price of $6.23 per share, with a total value of $105,287.00. Following the completion of the transaction, the insider now owns 37,900 shares of the company’s stock, valued at $236,117. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 49,400 shares of company stock valued at $302,912. 15.90% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System grew its position in Ocular Therapeutix by 22.9% during the first quarter. California State Teachers Retirement System now owns 43,920 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 8,181 shares in the last quarter. Bank of New York Mellon Corp grew its position in Ocular Therapeutix by 13.6% during the second quarter. Bank of New York Mellon Corp now owns 94,294 shares of the biopharmaceutical company’s stock worth $636,000 after buying an additional 11,276 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in Ocular Therapeutix by 39.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 53,570 shares of the biopharmaceutical company’s stock worth $349,000 after buying an additional 15,100 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Ocular Therapeutix during the first quarter worth about $102,000. Finally, MetLife Investment Advisors LLC purchased a new position in Ocular Therapeutix during the second quarter worth about $117,000. Institutional investors and hedge funds own 56.65% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

See Also: Relative Strength Index

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.